SMARCA2 and cancer: However, small molecule inhibitors developed to recapitulate the anti-proliferative effects of total protein loss, by targeting either the enzymatic region or the bromodomain, have proven substantially less effective [53,54], indicating that functions of SMARCA2/4 beyond the enzymatic are driving proliferation in the cancer setting.